Barclays PLC Purchases 696,447 Shares of Progyny, Inc. $PGNY

Key Points

• Barclays PLC increased its stake in Progyny by 79.2%, buying 696,447 shares to hold 1,575,470 shares (about 1.83% of the company) valued at roughly $33.9 million at quarter end.
• Progyny beat Q earnings with EPS $0.48 vs. $0.38 expectations and revenue of $318.4M (up 6.7% year-over-year), and issued FY2026 guidance of 1.83–1.95 EPS and Q1 guidance of 0.42–0.45.
• Analysts give Progyny a consensus "Moderate Buy" rating (nine Buys, four Holds) with an average price target of $29.09.

Barclays PLC boosted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 79.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,575,470 shares of the company's stock after purchasing an additional 696,447 shares during the period. Barclays PLC owned about 1.83% of Progyny worth $33,904,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Federated Hermes Inc. lifted its stake in Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company's stock valued at $30,000 after purchasing an additional 819 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of Progyny by 61.8% in the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company's stock valued at $50,000 after acquiring an additional 894 shares during the last quarter. Covestor Ltd lifted its stake in shares of Progyny by 164.9% in the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company's stock valued at $56,000 after acquiring an additional 1,624 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Progyny during the 2nd quarter valued at $77,000. Finally, USA Financial Formulas acquired a new stake in shares of Progyny during the 3rd quarter valued at $100,000. 94.93% of the stock is currently owned by institutional investors.

Insider Activity

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the sale, the executive vice president directly owned 89,879 shares of the company's stock, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 7,455 shares of company stock worth $129,515 in the last ninety days. 9.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. BTIG Research reduced their target price on shares of Progyny from $35.00 to $30.00 and set a "buy" rating on the stock in a report on Thursday, March 5th. Citigroup raised Progyny to an "outperform" rating in a report on Tuesday, January 20th. Truist Financial reduced their price target on Progyny from $34.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, March 2nd. Zacks Research downgraded Progyny from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 30th. Finally, Wall Street Zen raised Progyny from a "hold" rating to a "buy" rating in a research note on Saturday, January 3rd. Nine analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $29.09.

Progyny Stock Performance

Shares of PGNY opened at $17.91 on Wednesday. The firm has a market cap of $1.47 billion, a PE ratio of 27.55, a price-to-earnings-growth ratio of 1.22 and a beta of 1.01. Progyny, Inc. has a 52-week low of $16.75 and a 52-week high of $28.75. The business's 50 day moving average price is $22.79 and its two-hundred day moving average price is $22.85.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. During the same quarter in the previous year, the company earned $0.42 EPS. Progyny's quarterly revenue was up 6.7% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Research analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.